ZA946881B - Methods for treating gastrointestinal motility - Google Patents

Methods for treating gastrointestinal motility

Info

Publication number
ZA946881B
ZA946881B ZA946881A ZA946881A ZA946881B ZA 946881 B ZA946881 B ZA 946881B ZA 946881 A ZA946881 A ZA 946881A ZA 946881 A ZA946881 A ZA 946881A ZA 946881 B ZA946881 B ZA 946881B
Authority
ZA
South Africa
Prior art keywords
methods
gastrointestinal motility
treating gastrointestinal
gastric emptying
motility
Prior art date
Application number
ZA946881A
Other languages
English (en)
Inventor
Orville G Kolterman
Andrew A Young
Timothy J Rink
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of ZA946881B publication Critical patent/ZA946881B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA946881A 1993-09-07 1994-09-07 Methods for treating gastrointestinal motility ZA946881B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11838193A 1993-09-07 1993-09-07

Publications (1)

Publication Number Publication Date
ZA946881B true ZA946881B (en) 1995-10-30

Family

ID=22378228

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA946881A ZA946881B (en) 1993-09-07 1994-09-07 Methods for treating gastrointestinal motility

Country Status (23)

Country Link
US (4) US6114304A (pt)
EP (1) EP0717635B1 (pt)
JP (2) JP3821839B2 (pt)
KR (2) KR100391399B1 (pt)
CN (1) CN1134110A (pt)
AT (1) ATE197549T1 (pt)
AU (1) AU7685894A (pt)
BG (1) BG100463A (pt)
BR (1) BR9407424A (pt)
CA (1) CA2171207C (pt)
CZ (1) CZ69596A3 (pt)
DE (1) DE69426304T2 (pt)
DK (1) DK0717635T3 (pt)
ES (1) ES2154299T3 (pt)
GR (1) GR3035387T3 (pt)
HU (1) HUT73490A (pt)
NO (1) NO960899L (pt)
PT (1) PT717635E (pt)
RU (1) RU2177331C2 (pt)
SG (1) SG98356A1 (pt)
SK (1) SK31496A3 (pt)
WO (1) WO1995007098A1 (pt)
ZA (1) ZA946881B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
CA2171207C (en) * 1993-09-07 2010-03-30 Orville G. Kolterman Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
EP1053001B1 (en) * 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
ATE460942T1 (de) 1999-01-14 2010-04-15 Amylin Pharmaceuticals Inc Exendine zur glucagon suppression
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
JP2004514462A (ja) 2000-03-03 2004-05-20 シー・アール・バード・インク 複数吸引ポート付き内視鏡用組織癒着装置
ES2435094T3 (es) 2000-05-19 2013-12-18 C.R. Bard, Inc. Dispositivo y método de captura y sutura de tejido
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
WO2004024192A1 (en) * 2002-09-12 2004-03-25 University Of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1663289A2 (en) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
CA2556226A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8172857B2 (en) 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1888094B1 (en) 2005-03-31 2009-08-12 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
CN101405020A (zh) * 2006-03-23 2009-04-08 安米林药品公司 代谢疾病治疗中的内皮素和内皮素受体激动剂
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
ES2389747T3 (es) 2007-02-05 2012-10-31 Amylin Pharmaceuticals, Inc. Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
KR101673042B1 (ko) 2009-03-12 2016-11-04 키바이오사이언스 아게 당뇨병 및 대사 증후군의 치료
WO2010107874A2 (en) * 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
AR088636A1 (es) 2011-11-03 2014-06-25 Zealand Pharma As Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Gip-glp-1 이원 효능제 화합물 및 방법
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
DK3212218T3 (da) 2014-10-29 2021-08-30 Zealand Pharma As GIP-agonistforbindelser og fremgangsmåder
EP3271381B1 (en) 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin analogues
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
CA3043151A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018122278A1 (fr) 2016-12-27 2018-07-05 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
ES2917893T3 (es) 2017-07-27 2022-07-12 Adocia Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CN111683674A (zh) 2017-12-07 2020-09-18 阿道恰公司 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
WO2019115411A1 (fr) 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451394A (en) * 1982-10-25 1984-05-29 American Home Products Corporation Dodecapeptides preventing glucose and triglyceride assimilation
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4690486A (en) * 1985-04-29 1987-09-01 Texas Instruments Incorporated Four position interlacing apparatus
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5166192A (en) * 1989-05-09 1992-11-24 Mathias John R Treatment of motility disorders with a GnRH analog
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK0586589T3 (da) * 1991-05-24 1997-09-22 Amylin Pharmaceuticals Inc Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
JP2902115B2 (ja) * 1991-11-19 1999-06-07 アミリン・ファーマシューティカルズ,インコーポレイテッド 新規アミリン作動薬ペプチドおよびその使用
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
CA2171207C (en) * 1993-09-07 2010-03-30 Orville G. Kolterman Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists

Also Published As

Publication number Publication date
RU2177331C2 (ru) 2001-12-27
JP2004331674A (ja) 2004-11-25
GR3035387T3 (en) 2001-05-31
CN1134110A (zh) 1996-10-23
ATE197549T1 (de) 2000-12-15
CA2171207A1 (en) 1995-03-16
EP0717635A1 (en) 1996-06-26
NO960899D0 (no) 1996-03-06
CA2171207C (en) 2010-03-30
BR9407424A (pt) 1996-04-09
US5795861A (en) 1998-08-18
US20040097415A1 (en) 2004-05-20
DE69426304D1 (de) 2000-12-21
DE69426304T2 (de) 2001-03-15
AU7685894A (en) 1995-03-27
WO1995007098A1 (en) 1995-03-16
JPH09502443A (ja) 1997-03-11
HUT73490A (en) 1996-08-28
DK0717635T3 (da) 2000-12-11
ES2154299T3 (es) 2001-04-01
KR100391399B1 (ko) 2004-02-11
SK31496A3 (en) 1998-06-03
US6608029B1 (en) 2003-08-19
US7407934B2 (en) 2008-08-05
PT717635E (pt) 2001-04-30
US6114304A (en) 2000-09-05
JP3821839B2 (ja) 2006-09-13
KR20040004418A (ko) 2004-01-13
HU9600558D0 (en) 1996-05-28
KR100429966B1 (ko) 2004-05-04
SG98356A1 (en) 2003-09-19
NO960899L (no) 1996-05-06
EP0717635B1 (en) 2000-11-15
BG100463A (en) 1997-03-31
CZ69596A3 (en) 1997-06-11

Similar Documents

Publication Publication Date Title
ZA946881B (en) Methods for treating gastrointestinal motility
CA2262647A1 (en) Methods for regulating gastrointestinal motility
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
HK1042496A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bishosphatase
EP1618898A3 (en) Methods for regulating angiogenesis
NZ502610A (en) Use of lactobacillus for reduction of the fibrinogen level in blood
NZ504256A (en) Exendin 3 and 4 agonist compounds for treating diabetes
CA2257077A1 (en) Treatment of diarrhea
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
WO2003000242A3 (en) Method for the treatment of lymphedema using guaifenesin
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
DE69920885D1 (en) C-myc-bindendes protein "c-myc coding region determinant-binding protein (crd-bp)"
CA2340320A1 (en) Use of an angiogenic factor for the treatment of microascular angiopathies
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
CA2327439A1 (en) Combination therapy for the treatment of tumors
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
AP2000001950A0 (en) Paroxetine maleate.
EP1417971A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
WO1999064065A3 (en) Tumour therapy and imaging
PT979098E (pt) Metodo para o tratamento da hiperprolactinemia e de prolactinomas
ES8602799A1 (es) Un procedimiento para preparar 6-metilsulfoxido-espiro-(croman-4,4'-imidazolidin)-2',5'-diona